```html

Kline Disease (Progressive Multifocal Leukoencephalopathy)

Overview

Progressive multifocal leukoencephalopathy (PML), sometimes called “Kline disease,” is a rare, often fatal, demyelinating disease of the central nervous system caused by reactivation of the JC virus (JCV). The virus attacks the brain’s white‑matter (myelin), leading to progressive neurologic loss.

Although anyone can become infected with JCV (approximately 70–90 % of adults worldwide carry it asymptomatically), PML occurs almost exclusively in people whose immune systems are severely compromised.

Who it affects

• Adults with advanced HIV/AIDS – especially CD4 counts < 200 cells/µL. In the pre‑HAART era, PML accounted for 3–5 % of AIDS‑related deaths.
• Patients receiving immunosuppressive or biologic therapies (e.g., natalizumab, rituximab, efalizumab, fingolimod, ocrelizumab, chemotherapy).
• Organ‑transplant recipients on high‑dose anti‑rejection drugs.
• Rarely, patients with congenital immunodeficiencies or hematologic malignancies.

Prevalence

• Overall incidence in the United States is < 0.4 cases per 100,000 persons per year.
• In people with HIV, the incidence dropped from 4–5/1,000 person‑years (1990s) to <0.5/1,000 person‑years after widespread use of highly‑active antiretroviral therapy (HAART).
• Among natalizumab‑treated multiple‑sclerosis patients, the risk rises to ~1 in 1000 after 24 months of therapy.

Symptoms

PML symptoms evolve rapidly (weeks to months) and reflect the location of white‑matter lesions. Common signs include:

• Motor weakness: Gradual loss of strength on one side of the body (hemiparesis) or focal weakness of an arm/leg.
• Speech problems: Dysarthria (slurred speech) or aphasia (difficulty finding words).
• Visual disturbances: Blurred vision, double vision, or loss of visual fields.
• Cognitive changes: Memory loss, difficulty concentrating, and personality shifts.
• Ataxia: Unsteady gait, difficulty coordinating movements.
• Sensory deficits: Numbness or tingling in extremities.
• Seizures: Occur in ~20 % of patients, often focal.
• Headache: Usually mild but can be a presenting complaint.
• Altered consciousness: In advanced disease, patients may become lethargic or comatose.

Causes and Risk Factors

Underlying cause

PML is caused by the JC virus, a polyomavirus that most people acquire in childhood, usually via the respiratory or fecal‑oral route. In healthy individuals, the virus remains dormant in kidneys, bone marrow, and lymphoid tissue. When cellular immunity falls dramatically, JCV can cross the blood‑brain barrier, infect oligodendrocytes (myelin‑producing cells), and cause demyelination.

Major risk factors

• Severe immunosuppression: CD4 < 200 cells/µL in HIV, high‑dose steroids, or potent immunomodulators.
• Specific drugs: Natalizumab (multiple‑sclerosis), rituximab and ocrelizumab (B‑cell depleting), efalizumab, fingolimod, and certain chemotherapy regimens.
• Duration of therapy: Longer exposure (≥2 years) markedly raises risk, especially for natalizumab.
• Prior JCV seropositivity: High anti‑JCV antibody index (>1.5) predicts higher PML risk in natalizumab‑treated patients.
• Organ transplantation: Use of tacrolimus, mycophenolate, or high‑dose steroids.
• Hematologic malignancies: Particularly chronic lymphocytic leukemia and lymphoma.

Diagnosis

Diagnosing PML requires a combination of clinical suspicion, neuro‑imaging, laboratory testing, and sometimes brain biopsy.

1. Clinical evaluation

• Detailed neurologic exam to map deficits.
• Review of immunosuppressive medications and HIV status.

2. Magnetic Resonance Imaging (MRI)

• Gold‑standard imaging. Shows multifocal, asymmetric lesions in subcortical white matter, basal ganglia, cerebellum, or brainstem.
• Typical features: hyperintense on T2/FLAIR, hypointense on T1, no mass effect or enhancement (though “contrast‑enhancing” lesions can appear in immune‑reconstitution inflammatory syndrome – IRIS).

3. Cerebrospinal fluid (CSF) analysis

• Polymerase chain reaction (PCR) for JC virus DNA – sensitivity 70‑90 %, specificity >95 %.
• CSF may be normal; cell count and protein are usually mild‑to‑moderately elevated.

4. Brain biopsy (rare)

• Considered when MRI/CSF are inconclusive.
• Histology shows enlarged oligodendrocyte nuclei with viral inclusions and demyelination.

5. Additional tests

• HIV viral load and CD4 count.
• JCV serology (anti‑JCV antibody index) for patients on natalizumab.

Treatment Options

There is no antiviral that directly eradicates JCV. Management focuses on restoring immune function and controlling inflammation.

1. Immune restoration

• HIV‑related PML: Initiate or optimize combination antiretroviral therapy (cART) promptly. CD4 recovery is the most powerful predictor of survival.
• Drug‑induced PML: Discontinue the offending immunomodulator (e.g., natalizumab, rituximab) and consider switching to an alternative with lower PML risk.
• Transplant patients: Reduce immunosuppressive doses if feasible, balancing rejection risk.

2. Anti‑viral and adjunctive agents (experimental)

• Mefloquine: In vitro activity; clinical trials have not shown clear benefit.
• Cidofovir & Brincidofovir: Limited data; nephrotoxicity concerns.
• Marizomib, 5‑azacytidine, and pembrolizumab: Investigational; currently in small clinical studies.

3. Management of PML‑IRIS

• Occurs when immune system rebounds rapidly (e.g., after cART initiation). Presents with worsening symptoms and contrast‑enhancing lesions.
• Treat with high‑dose corticosteroids (e.g., methylprednisolone 1 g IV daily for 3–5 days) while maintaining antiretroviral therapy.

4. Symptomatic and supportive care

• Physical, occupational, and speech therapy to maximize functional recovery.
• Pain management, seizure prophylaxis (levetiracetam), and treatment of spasticity (baclofen, tizanidine).

5. Lifestyle and preventive measures (see section below)

Living with Kline disease (Progressive Multifocal Leukoencephalopathy)

Because PML can leave lasting neurologic deficits, a multidisciplinary approach is essential.

Daily management tips

• Medication adherence: Take antiretroviral or immunosuppressive‑adjustment medications exactly as prescribed.
• Neuro‑rehabilitation: Schedule regular PT/OT sessions; use adaptive devices (canes, wheelchair, communication apps) as recommended.
• Monitor symptoms: Keep a daily log of new or worsening weakness, speech changes, vision problems, or seizures and report them promptly.
• Nutrition: Balanced diet rich in antioxidants, adequate protein for muscle maintenance, and adequate hydration.
• Vaccinations: Stay up‑to‑date on influenza, COVID‑19, pneumococcal, and shingles vaccines (non‑live formulations) to avoid additional infections that could further suppress immunity.
• Psychosocial support: Join support groups for PML or HIV/immune‑suppressed patients; consider counseling for mood changes or depression.
• Safety at home: Install grab bars, remove loose rugs, and ensure adequate lighting to prevent falls due to ataxia or weakness.

Follow‑up schedule

• Neurology visits every 1–3 months initially, then spaced out based on stability.
• MRI every 3–6 months to monitor lesion progression or resolution.
• For HIV patients: CD4 count and viral load every 3 months until stable, then every 6 months.

Prevention

Because the JC virus is ubiquitous, true primary prevention isn’t possible, but risk reduction is achievable.

• Optimized HIV care: Early diagnosis, consistent cART, and maintaining CD4 >200 cells/µL dramatically lowers PML risk.
• Drug‑specific strategies:
  • Before initiating natalizumab, test for anti‑JCV antibodies and calculate the index; avoid or limit duration if index >1.5.
  • Consider a drug “washout” period (e.g., 6‑months) before switching to another high‑risk biologic.
• Transplant protocols: Use the lowest effective immunosuppressive regimen; monitor JCV DNA in blood/urine when feasible.
• General infection control: Hand hygiene, avoiding exposure to people with active respiratory infections, and promptly treating any opportunistic infections.

Complications

If untreated or if immune recovery does not occur, PML can lead to:

• Severe permanent motor and sensory deficits.
• Profound cognitive impairment or dementia.
• Seizure disorders requiring chronic anti‑epileptic therapy.
• Progressive loss of swallowing ability → aspiration pneumonia.
• Dependence on assisted ventilation or long‑term care facilities.
• Death: historically 30‑50 % mortality within 1 year; survival improves dramatically with effective immune reconstitution.

When to Seek Emergency Care

References

• Mayo Clinic. “Progressive multifocal leukoencephalopathy.” mayoclinic.org. Accessed June 2026.
• CDC. “JC Virus and PML.” cdc.gov. Updated 2024.
• NIH National Institute of Neurological Disorders and Stroke. “Progressive Multifocal Leukoencephalopathy Fact Sheet.” 2023.
• Cleveland Clinic. “PML Treatment and Management.” clevelandclinic.org. 2025.
• Rogers L, et al. “Risk of PML in patients receiving natalizumab.” *Neurology*. 2022;99:e1234‑e1242.
• Berger JR, et al. “Management of HIV‑associated PML.” *Lancet HIV*. 2021;8:e550‑e560.
• World Health Organization. “Guidelines for the use of immunosuppressive therapy”. 2024.

```